Therefore, the ACM secretome may be creating a therapeutic niche for the use of ICBs to harness anti-tumour immunity through blocking inhibitory signalling of TIGIT A2aR, PD-L2 and CD160 on the surface of T cells (Hintzen et al. 1994). This evidence concerns the gene CD160 and neoplasm.